There are 14 listed Pharma API stocks in India. The largest by market value are Aarti Pharmalabs (₹9,189 crore), Innova Captab (₹6,009 crore), Orchid Pharma (₹5,724 crore), Senores Pharmaceuticals and Gujarat Themis Biosyn, at prices of 18 November 2026. 7 of the 14 companies we track are beating the Nifty 500 on share price over recent months.
Pharma API: Aarti Drugs Ltd owns the largest revenue base; Senores Pharmaceuticals Ltd has the fastest current growth.
The main question: the biggest companies are not always the ones changing the most.
Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.
How big is the Pharma API sector?
There are 14 listed Pharma API companies on this page, worth ₹46,500 cr together at prices of 18 November 2026. Aarti Pharmalabs alone is ₹9,190 cr, about 20% of the total.
Market values at prices of 18 November 2026.
What did Pharma API managements say about July to September 2026?
13 of 20 Pharma - API companies held a results call for July to September 2026. Cohance Lifesciences guided: H2 FY27 revenue and operating profit to grow on a year earlier with H2 stronger than H1 on deliveries and mix.
Cohance Lifesciences call 6 November 2026
“Based on the visibility we have today, we continue to expect H2 FY27 to deliver year-on-year growth in both revenue and EBITDA.”Umang Vohra
Guided: H2 FY27 revenue and operating profit to grow on a year earlier with H2 stronger than H1 on deliveries and mix.
Supriya Lifescience call 6 November 2026
“While margins could moderate in FY27 due to this, we view this as an aberration rather than a change in the underlying DNA of the business.”Krishna Raghunathan
Guided: FY27 revenue ₹1,000 crore.
Symbiotec Pharmalab call 6 November 2026
“Three years ago, Symbiotec Pharmalab Ltd. was just an API company. Today, it is an API company with a signed US injectable partner, a fermentation CDMO business with its first 2 partners already in place, and a biologics plant under commissioning.”Anish Sapani
Guided: FY27 revenue growth around 20% and operating profit growth around 25% within 5pp either side.
Shilpa Medicare call 5 November 2026
“I want to start not with the quarter numbers-we will get to those, and they are the best in our history-but by informing all our investors that the hardest years, the years of investing ahead of revenue, are behind us. The years of harvesting are beginning.”Keshav Bhutada, opening remarks
Guided: More than 15 new oncology generics plus integrated peptide build commissioning planned by end FY27.
SMS Pharmaceuticals call 5 November 2026
“Backward integration gives us a structural cost advantage, not a temporary pricing benefit, and this quarter shows that clearly.”Vamsi Krishna Potluri
Guided: FY27 revenue growth and operating margin to exceed 15% and 20% respectively.
Aarti Drugs call 4 November 2026
“These gains in product mix, backward integration, and cost efficiency are structural, and they will stay with us even as the pricing environment normalizes over time.”Adish Patil
Guided: Consolidated operating margin 15% sustainable despite quarterly strength with conservative stance.
Anlon Healthcare call 3 November 2026
“In this business, registration rather than price is the gating factor.”Punith Kumar Rasadiya
Guided: FY27 revenue ₹380-400 crore.
IOL Chemicals & Pharmaceuticals call 2 November 2026
“Our non-ibuprofen portfolio maintained its growth momentum, registering approximately 70% year-on-year revenue growth during Q2 and contributing 45% of pharmaceutical revenue, compared with 38% in the corresponding quarter last year.”Abhay Raj Singh
Guided: FY27 revenue growth 25% plus on value basis with second half similar to first.
5 more Pharma - API calls held for July to September 2026 are not shown here, to keep the page fast.
From the results calls for July to September 2026.
Is money moving into Pharma API stocks? Who is adding capacity?
Big funds, foreign and Indian, kept their stake about the same over the last two quarters. Founders and promoters kept theirs about the same.
- Spending on new plants and equipment was ₹1,622 crore in the last 12 months, 2% less than a year before.
- Projects still being built shrank 2% in a year.
Big funds = foreign and Indian institutions, change in their share of ownership across 15 Pharma - API companies, in percentage points.
Ownership and spending as of 10 October 2026.
What to watch next in Pharma API stocks?
The next things that show whether the Pharma - API story is on course. First: Innova's Jammu plant stays profitable as sales increase through July to September 2026.
- Aarti Pharmalabs' second-half development-work sales increase enough to offset normalizing Xanthine pricing.
- Senores converts approved products into commercial sales and progresses the planned manufacturing approval.
- Orchid delivers the planned December 2026 Cefiderocol commissioning and March 2027 7-ACA commercial batch.
- The next sector quarter confirms that the June year-on-year profit recovery continues without another margin decline.
What would change the story
The next reported sector quarter showing profit below the same quarter a year earlier, together with a falling operating margin, would break the earnings-recovery case supporting this second breakout.
From our industry review of 10 October 2026.
Which are the biggest Pharma API stocks in India?
The largest Pharma API stocks in India by market value are Aarti Pharmalabs (₹9,189 crore), Innova Captab (₹6,009 crore) and Orchid Pharma (₹5,724 crore), at prices of 18 Nov 2026.
- Aarti Pharmalabs: ₹1,013.40 | market value ₹9,189 crore | P/E 36.4
- Innova Captab: ₹1,050.10 | market value ₹6,009 crore | P/E 32.2
- Orchid Pharma: ₹955.95 | market value ₹5,724 crore | P/E 129.2
- Senores Pharmaceuticals: ₹1,092.60 | market value ₹5,031 crore | P/E 35.1
- Gujarat Themis Biosyn: ₹362.80 | market value ₹4,722 crore | P/E 88.9
- Aarti Drugs: ₹505.75 | market value ₹4,616 crore | P/E 20.1
- Ind-Swift Laboratories: ₹336.75 | market value ₹2,929 crore | P/E 32.4
- Beta Drugs: ₹1,802.30 | market value ₹2,004 crore | P/E 37.1
- Jagsonpal Pharmaceuticals: ₹208.27 | market value ₹1,376 crore | P/E 29.3
- Fermenta Biotech: ₹456.40 | market value ₹1,343 crore | P/E 25.1
The other 4 Pharma API companies are in the full list below.
Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 18 Nov 2026; the score list below uses the weekly figures.
Which are the Pharma API stocks, ranked?
Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). The scores come from our weekly scan.
- 1Innova Captab LtdINNOVACAP · ₹6,010 cr66.5of 100favourable · strongest on profit growth and relative strength versus sector
- 2Aarti Drugs LtdAARTIDRUGS · ₹4,620 cr66.3of 100favourable · strongest on 13-week relative-strength change and relative strength versus sector
- 3Senores Pharmaceuticals LtdSENORES · ₹5,030 cr60.3of 100mixed, leaning good · strongest on profit growth and revenue growth
- 4Anuh Pharma LtdANUHPHR · ₹797 cr59.7of 100mixed, leaning good · strongest on ROCE improvement and own-history P/E
- 5Beta Drugs LtdBETA · ₹2,000 cr56.0of 100mixed, leaning good · strongest on ROCE and profit growth
- 6Kopran LtdKOPRAN · ₹1,290 cr53.9of 100mixed, leaning good · strongest on ROCE improvement and margin improvement
- 7Ind-Swift Laboratories LtdINDSWFTLAB · ₹2,930 cr49.9of 100mixed, leaning weak · strongest on relative strength versus sector and margin improvement
- 8Aarti Pharmalabs LtdAARTIPHARM · ₹9,190 cr49.1of 100mixed, leaning weak · strongest on margin improvement and relative strength versus the benchmark
- 9Jagsonpal Pharmaceuticals LtdJAGSNPHARM · ₹1,380 cr47.5of 100mixed, leaning weak · strongest on ROCE and ROCE improvement
- 10Gujarat Themis Biosyn LtdGUJTHEM · ₹4,720 cr47.0of 100mixed, leaning weak · strongest on 13-week relative-strength change and ROCE
Is there a Nifty Pharma API index, and what is in it?
All 14 listed Indian Pharma - API companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Pharma - API index; the exchange publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. One large company cannot set the reading.
- Aarti Pharmalabs Ltd₹9,190 cr
- Innova Captab Ltd₹6,010 cr
- Senores Pharmaceuticals Ltd₹5,030 cr
- Orchid Pharma Ltd₹5,720 cr
- Gujarat Themis Biosyn Ltd₹4,720 cr
- Aarti Drugs Ltd₹4,620 cr
- Ind-Swift Laboratories Ltd₹2,930 cr
- Beta Drugs Ltd₹2,000 cr
- Jagsonpal Pharmaceuticals Ltd₹1,380 cr
- Kopran Ltd₹1,290 cr
- Fermenta Biotech Ltd₹1,340 cr
- Themis Medicare Ltd₹888 cr
- Anuh Pharma Ltd₹797 cr
- Wanbury Ltd₹609 cr
How many Pharma API companies are listed in India?
14 Pharma API companies in the Pharma - API industry group have a page on Sector Alpha, and all 14 are listed below, largest first. The largest is Aarti Pharmalabs (₹9,189 crore) and the smallest with a market value is Wanbury.
| Company | Market value |
|---|---|
| 1. Aarti Pharmalabs Ltd AARTIPHARM | ₹9,189 crore |
| 2. Innova Captab Ltd INNOVACAP | ₹6,009 crore |
| 3. Orchid Pharma Ltd ORCHPHARMA | ₹5,724 crore |
| 4. Senores Pharmaceuticals Ltd SENORES | ₹5,031 crore |
| 5. Gujarat Themis Biosyn Ltd GUJTHEM | ₹4,722 crore |
| 6. Aarti Drugs Ltd AARTIDRUGS | ₹4,616 crore |
| 7. Ind-Swift Laboratories Ltd INDSWFTLAB | ₹2,929 crore |
| 8. Beta Drugs Ltd BETA | ₹2,004 crore |
| 9. Jagsonpal Pharmaceuticals Ltd JAGSNPHARM | ₹1,376 crore |
| 10. Fermenta Biotech Ltd FERMENTA | ₹1,343 crore |
| 11. Kopran Ltd KOPRAN | ₹1,285 crore |
| 12. Themis Medicare Ltd THEMISMED | ₹888 crore |
| 13. Anuh Pharma Ltd ANUHPHR | ₹797 crore |
| 14. Wanbury Ltd WANBURY | ₹609 crore |
How have Pharma API stocks moved against NIFTY 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 26% ahead of NIFTY 500. Earnings across its companies fell 8% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 33 weeks running.
Price up, without the fundamentals confirming. 7 of 14 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high).
Ahead of NIFTY 500 on the three-month view for 33 weeks running; 12 of the 14 companies in the industry index above their 200-day average (1 fewer than four weeks earlier); 7 of those 14 pass the momentum test (2 more than four weeks earlier); earnings rising at 9 of the 14 that report earnings.
Ahead of NIFTY 500 for 33 weeks running and +40.8% over a year, with 5 → 7 of 14 stocks participating. Earnings mixed, 9 of 14 members have higher trailing twelve-month earnings than a year ago.
1Y
Pharma - API against NIFTY 500
Both lines start at 200 in the first week shown
- Pharma API 289
- NIFTY 500 200
| Week ending | Pharma API | NIFTY 500 |
|---|---|---|
| 21 Nov 2025 | 200 | 200 |
| 28 Nov 2025 | 201 | 201 |
| 5 Dec 2025 | 197 | 200 |
| 12 Dec 2025 | 203 | 199 |
| 19 Dec 2025 | 201 | 199 |
| 26 Dec 2025 | 205 | 200 |
| 2 Jan 2026 | 207 | 203 |
| 9 Jan 2026 | 197 | 197 |
| 16 Jan 2026 | 197 | 197 |
| 23 Jan 2026 | 185 | 191 |
| 30 Jan 2026 | 188 | 194 |
| 6 Feb 2026 | 197 | 197 |
| 13 Feb 2026 | 194 | 196 |
| 20 Feb 2026 | 193 | 197 |
| 27 Feb 2026 | 191 | 195 |
| 6 Mar 2026 | 185 | 189 |
| 13 Mar 2026 | 183 | 180 |
| 20 Mar 2026 | 184 | 179 |
| 27 Mar 2026 | 179 | 177 |
| 3 Apr 2026 | 186 | 176 |
| 10 Apr 2026 | 197 | 188 |
| 17 Apr 2026 | 201 | 192 |
| 24 Apr 2026 | 204 | 190 |
| 1 May 2026 | 208 | 191 |
| 8 May 2026 | 214 | 194 |
| 15 May 2026 | 210 | 189 |
| 22 May 2026 | 215 | 190 |
| 29 May 2026 | 225 | 190 |
| 5 Jun 2026 | 226 | 189 |
| 12 Jun 2026 | 237 | 190 |
| 19 Jun 2026 | 243 | 195 |
| 26 Jun 2026 | 251 | 194 |
| 3 Jul 2026 | 255 | 196 |
| 10 Jul 2026 | 269 | 196 |
| 17 Jul 2026 | 270 | 196 |
| 24 Jul 2026 | 267 | 193 |
| 31 Jul 2026 | 269 | 197 |
| 7 Aug 2026 | 272 | 199 |
| 14 Aug 2026 | 280 | 198 |
| 21 Aug 2026 | 286 | 198 |
| 28 Aug 2026 | 296 | 198 |
| 4 Sep 2026 | 298 | 195 |
| 11 Sep 2026 | 301 | 192 |
| 18 Sep 2026 | 300 | 192 |
| 25 Sep 2026 | 306 | 190 |
| 2 Oct 2026 | 303 | 184 |
| 9 Oct 2026 | 288 | 184 |
| 16 Oct 2026 | 281 | 187 |
| 23 Oct 2026 | 262 | 180 |
| 30 Oct 2026 | 270 | 184 |
| 6 Nov 2026 | 281 | 197 |
| 13 Nov 2026 | 289 | 200 |
3Y
Pharma - API against NIFTY 500
Both lines start at 200 in the first week shown, every 2nd week shown
- Pharma API 476
- NIFTY 500 269
| Week ending | Pharma API | NIFTY 500 |
|---|---|---|
| 24 Nov 2023 | 200 | 200 |
| 1 Dec 2023 | 206 | 205 |
| 15 Dec 2023 | 217 | 217 |
| 29 Dec 2023 | 228 | 220 |
| 12 Jan 2024 | 243 | 224 |
| 26 Jan 2024 | 236 | 220 |
| 9 Feb 2024 | 249 | 226 |
| 23 Feb 2024 | 265 | 230 |
| 8 Mar 2024 | 251 | 232 |
| 22 Mar 2024 | 242 | 227 |
| 5 Apr 2024 | 262 | 235 |
| 19 Apr 2024 | 258 | 231 |
| 3 May 2024 | 259 | 238 |
| 17 May 2024 | 264 | 239 |
| 31 May 2024 | 247 | 239 |
| 14 Jun 2024 | 269 | 252 |
| 28 Jun 2024 | 268 | 256 |
| 12 Jul 2024 | 285 | 262 |
| 26 Jul 2024 | 317 | 264 |
| 9 Aug 2024 | 324 | 260 |
| 23 Aug 2024 | 342 | 265 |
| 6 Sep 2024 | 353 | 266 |
| 20 Sep 2024 | 357 | 274 |
| 4 Oct 2024 | 345 | 267 |
| 18 Oct 2024 | 355 | 266 |
| 1 Nov 2024 | 356 | 259 |
| 15 Nov 2024 | 355 | 249 |
| 29 Nov 2024 | 380 | 257 |
| 13 Dec 2024 | 393 | 265 |
| 27 Dec 2024 | 385 | 254 |
| 10 Jan 2025 | 375 | 247 |
| 24 Jan 2025 | 365 | 242 |
| 7 Feb 2025 | 366 | 245 |
| 21 Feb 2025 | 308 | 235 |
| 7 Mar 2025 | 313 | 232 |
| 21 Mar 2025 | 320 | 241 |
| 4 Apr 2025 | 311 | 236 |
| 18 Apr 2025 | 321 | 246 |
| 2 May 2025 | 303 | 249 |
| 16 May 2025 | 332 | 259 |
| 30 May 2025 | 338 | 258 |
| 13 Jun 2025 | 359 | 260 |
| 27 Jun 2025 | 349 | 268 |
| 11 Jul 2025 | 360 | 264 |
| 25 Jul 2025 | 363 | 261 |
| 8 Aug 2025 | 348 | 254 |
| 22 Aug 2025 | 359 | 261 |
| 5 Sep 2025 | 355 | 259 |
| 19 Sep 2025 | 365 | 266 |
| 3 Oct 2025 | 358 | 261 |
| 17 Oct 2025 | 341 | 268 |
| 31 Oct 2025 | 354 | 269 |
| 14 Nov 2025 | 339 | 270 |
| 28 Nov 2025 | 332 | 271 |
| 12 Dec 2025 | 335 | 269 |
| 26 Dec 2025 | 339 | 270 |
| 9 Jan 2026 | 326 | 266 |
| 23 Jan 2026 | 306 | 257 |
| 6 Feb 2026 | 325 | 266 |
| 20 Feb 2026 | 319 | 265 |
| 6 Mar 2026 | 305 | 255 |
| 20 Mar 2026 | 304 | 242 |
| 3 Apr 2026 | 308 | 237 |
| 17 Apr 2026 | 333 | 259 |
| 1 May 2026 | 344 | 257 |
| 15 May 2026 | 347 | 255 |
| 29 May 2026 | 372 | 257 |
| 12 Jun 2026 | 390 | 256 |
| 26 Jun 2026 | 414 | 262 |
| 10 Jul 2026 | 444 | 265 |
| 24 Jul 2026 | 440 | 260 |
| 7 Aug 2026 | 449 | 269 |
| 21 Aug 2026 | 472 | 267 |
| 4 Sep 2026 | 491 | 264 |
| 18 Sep 2026 | 495 | 259 |
| 2 Oct 2026 | 501 | 248 |
| 16 Oct 2026 | 464 | 252 |
| 30 Oct 2026 | 446 | 248 |
| 13 Nov 2026 | 476 | 269 |
5Y
Pharma - API against NIFTY 500
Both lines start at 200 in the first week shown, every 4th week shown
- Pharma API 705
- NIFTY 500 323
| Week ending | Pharma API | NIFTY 500 |
|---|---|---|
| 26 Nov 2021 | 200 | 200 |
| 17 Dec 2021 | 205 | 200 |
| 14 Jan 2022 | 218 | 214 |
| 11 Feb 2022 | 206 | 203 |
| 11 Mar 2022 | 195 | 194 |
| 8 Apr 2022 | 216 | 209 |
| 6 May 2022 | 204 | 192 |
| 3 Jun 2022 | 197 | 191 |
| 1 Jul 2022 | 183 | 182 |
| 29 Jul 2022 | 196 | 199 |
| 26 Aug 2022 | 193 | 206 |
| 23 Sep 2022 | 209 | 205 |
| 21 Oct 2022 | 205 | 205 |
| 18 Nov 2022 | 204 | 211 |
| 16 Dec 2022 | 208 | 213 |
| 13 Jan 2023 | 203 | 209 |
| 10 Feb 2023 | 190 | 204 |
| 10 Mar 2023 | 183 | 200 |
| 7 Apr 2023 | 190 | 201 |
| 5 May 2023 | 214 | 208 |
| 2 Jun 2023 | 221 | 215 |
| 30 Jun 2023 | 234 | 223 |
| 28 Jul 2023 | 249 | 230 |
| 25 Aug 2023 | 266 | 229 |
| 22 Sep 2023 | 278 | 235 |
| 20 Oct 2023 | 289 | 234 |
| 17 Nov 2023 | 294 | 239 |
| 15 Dec 2023 | 320 | 260 |
| 12 Jan 2024 | 359 | 269 |
| 9 Feb 2024 | 369 | 271 |
| 8 Mar 2024 | 371 | 278 |
| 5 Apr 2024 | 387 | 282 |
| 3 May 2024 | 383 | 285 |
| 31 May 2024 | 366 | 287 |
| 28 Jun 2024 | 397 | 307 |
| 26 Jul 2024 | 469 | 317 |
| 23 Aug 2024 | 506 | 318 |
| 20 Sep 2024 | 528 | 329 |
| 18 Oct 2024 | 524 | 319 |
| 15 Nov 2024 | 526 | 299 |
| 13 Dec 2024 | 581 | 318 |
| 10 Jan 2025 | 555 | 296 |
| 7 Feb 2025 | 542 | 294 |
| 7 Mar 2025 | 463 | 278 |
| 4 Apr 2025 | 459 | 283 |
| 2 May 2025 | 448 | 299 |
| 30 May 2025 | 500 | 310 |
| 27 Jun 2025 | 516 | 321 |
| 25 Jul 2025 | 537 | 313 |
| 22 Aug 2025 | 530 | 313 |
| 19 Sep 2025 | 540 | 319 |
| 17 Oct 2025 | 505 | 321 |
| 14 Nov 2025 | 502 | 324 |
| 12 Dec 2025 | 496 | 323 |
| 9 Jan 2026 | 482 | 319 |
| 6 Feb 2026 | 480 | 319 |
| 6 Mar 2026 | 451 | 306 |
| 3 Apr 2026 | 455 | 285 |
| 1 May 2026 | 509 | 308 |
| 29 May 2026 | 549 | 308 |
| 26 Jun 2026 | 612 | 314 |
| 24 Jul 2026 | 651 | 312 |
| 21 Aug 2026 | 698 | 320 |
| 18 Sep 2026 | 732 | 311 |
| 16 Oct 2026 | 686 | 303 |
| 13 Nov 2026 | 705 | 323 |
Earnings, each company rebased to 100, the sector takes the median
Latest quarter July to September 2026: 169.4, from 10 companies
| Quarter | Median earnings index |
|---|---|
| Apr 2022 | 100.0 (4 companies) |
| Jul 2022 | 100.0 (10 companies) |
| Oct 2022 | 101.5 (9 companies) |
| Jan 2023 | 107.6 (11 companies) |
| Apr 2023 | 111.2 (10 companies) |
| Jul 2023 | 108.6 (11 companies) |
| Oct 2023 | 112.0 (10 companies) |
| Jan 2024 | 122.1 (11 companies) |
| Apr 2024 | 121.8 (10 companies) |
| Jul 2024 | 124.1 (12 companies) |
| Oct 2024 | 109.3 (11 companies) |
| Jan 2025 | 100.5 (11 companies) |
| Apr 2025 | 107.1 (11 companies) |
| Jul 2025 | 115.1 (11 companies) |
| Oct 2025 | 107.6 (11 companies) |
| Jan 2026 | 103.6 (11 companies) |
| Apr 2026 | 101.6 (11 companies) |
| Jul 2026 | 169.4 (10 companies) |
Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 14 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.
Are Pharma API stocks outperforming NIFTY 500?
Pharma - API has done better than the NIFTY 500 by 20.4% over the last 52 weeks. Over 13 weeks the gap is a lead of 2.6%. Ind-Swift Laboratories Ltd is the strongest against the sector itself at +59.5%. Readings are as of 13 November 2026.
Relative-strength score for the industry: 20.2 as of 13 November 2026 (consolidation, falling).
What is the bottom line on Pharma API stocks?
Pharma - API has done better than the NIFTY 500 by 20.4% over 52 weeks and by 2.6% over 13 weeks. 7 of 14 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 3 of the 8 with a long enough price history are ahead of the industry itself.
How does each Pharma API stock score?
A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.
Innova Captab Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 90% evidence confidence.
- 1Innova Captab LtdINNOVACAP · leader · favourable · 90% evidence66.5out of 100
How the score adds up
Growth & earnings 25.5/35 · Revenue 36.8% · PAT 32.8% · OPM change 0 pp · 100% evidenceCapital efficiency 12.4/25 · ROCE 15% (year to Mar 2026) · OPM 14.1% · 100% evidenceValuation 11.6/20 · P/E 36× · PEG — · 50% evidenceRelative strength 17.0/20 · RS sector 17.1% · RS bench 29.8% · 1Y 38.3% · 100% evidence · 12 of 12 weeks aheadExact sum: 25.5 + 12.4 + 11.6 + 17 = 66.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 2Aarti Drugs LtdAARTIDRUGS · turning · favourable · 90% evidence66.3out of 100
How the score adds up
Growth & earnings 22.7/35 · Revenue 15.1% · PAT 15.1% · OPM change 3 pp · 100% evidenceCapital efficiency 13.9/25 · ROCE 12% (year to Mar 2026) · OPM 16.3% · 100% evidenceValuation 12.4/20 · P/E 20.2× · PEG — · 50% evidenceRelative strength 17.3/20 · RS sector 10.1% · RS bench 24.1% · 1Y 14.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 22.7 + 13.9 + 12.4 + 17.3 = 66.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 3Senores Pharmaceuticals LtdSENORES · quiet · mixed, leaning good · 75% evidence60.3out of 100
How the score adds up
Growth & earnings 27.8/35 · Revenue 38.9% · PAT 62.4% · OPM change −1 pp · 95% evidenceCapital efficiency 16.4/25 · ROCE 15.1% (year to Mar 2026) · OPM 30.2% · 76% evidenceValuation 9.0/20 · P/E 37.7× · PEG — · 15% evidenceRelative strength 7.1/20 · RS sector −4.1% · RS bench 6% · 1Y 33.3% · 100% evidence · 5 of 12 weeks aheadExact sum: 27.8 + 16.4 + 9 + 7.1 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 4Anuh Pharma LtdANUHPHR · breaking out · mixed, leaning good · 90% evidence59.7out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue 6.6% · PAT 23.7% · OPM change 3 pp · 100% evidenceCapital efficiency 13.9/25 · ROCE 14.9% (year to Mar 2026) · OPM 9.2% · 100% evidenceValuation 14.2/20 · P/E 16.7× · PEG — · 50% evidenceRelative strength 7.1/20 · RS sector −11.6% · RS bench −0.2% · 1Y 0% · 100% evidence · 9 of 12 weeks aheadExact sum: 24.5 + 13.9 + 14.2 + 7.1 = 59.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 5Beta Drugs LtdBETA · quiet · mixed, leaning good · 67% evidence56.0out of 100
How the score adds up
Growth & earnings 19.4/35 · Revenue 15.3% · PAT 26.2% · OPM change 1 pp · 95% evidenceCapital efficiency 18.4/25 · ROCE 19.2% (year to Mar 2026) · OPM 21.9% · 76% evidenceValuation 8.0/20 · P/E 37.4× · PEG — · 50% evidenceRelative strength 10.2/20 · RS sector — · RS bench 3.1% · 1Y 8.5% · 25% evidence · 4 of 12 weeks aheadExact sum: 19.4 + 18.4 + 8 + 10.2 = 56 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Kopran LtdKOPRAN · breaking out · mixed, leaning good · 66% evidence53.9out of 100
How the score adds up
Growth & earnings 27.9/35 · Revenue 34.1% · PAT 100% · OPM change 11.8 pp · 74% evidenceCapital efficiency 7.0/25 · ROCE 6.7% (year to Mar 2026) · OPM 7.3% · 100% evidenceValuation 6.7/20 · P/E 32.6× · PEG — · 50% evidenceRelative strength 12.3/20 · RS sector — · RS bench 55.1% · 1Y 106.8% · 25% evidence · 11 of 12 weeks aheadExact sum: 27.9 + 7 + 6.7 + 12.3 = 53.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 7Ind-Swift Laboratories LtdINDSWFTLAB · leader · mixed, leaning weak · 82% evidence49.9out of 100
How the score adds up
Growth & earnings 19.8/35 · Revenue 29.9% · PAT −64.1% · OPM change 14.3 pp · 95% evidenceCapital efficiency 8.3/25 · ROCE 4.9% (year to Mar 2026) · OPM 18.8% · 76% evidenceValuation 7.2/20 · P/E 34.8× · PEG — · 50% evidenceRelative strength 14.6/20 · RS sector 59.5% · RS bench 71.3% · 1Y 234.9% · 100% evidence · 12 of 12 weeks aheadExact sum: 19.8 + 8.3 + 7.2 + 14.6 = 49.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Aarti Pharmalabs LtdAARTIPHARM · leader · mixed, leaning weak · 75% evidence49.1out of 100
How the score adds up
Growth & earnings 17.3/35 · Revenue 13.4% · PAT 6.7% · OPM change 4 pp · 100% evidenceCapital efficiency 12.4/25 · ROCE 10.7% (year to Mar 2026) · OPM 22.1% · 100% evidenceValuation 7.6/20 · P/E 35.8× · PEG — · 50% evidenceRelative strength 11.8/20 · RS sector — · RS bench 28.3% · 1Y 46% · 25% evidence · 12 of 12 weeks aheadExact sum: 17.3 + 12.4 + 7.6 + 11.8 = 49.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Jagsonpal Pharmaceuticals LtdJAGSNPHARM · quiet · mixed, leaning weak · 90% evidence47.5out of 100
How the score adds up
Growth & earnings 12.9/35 · Revenue 6% · PAT −27% · OPM change −1 pp · 100% evidenceCapital efficiency 18.9/25 · ROCE 22.7% (year to Mar 2026) · OPM 21% · 100% evidenceValuation 11.0/20 · P/E 30.4× · PEG — · 50% evidenceRelative strength 4.7/20 · RS sector −10.2% · RS bench 0.9% · 1Y 3.3% · 100% evidence · 5 of 12 weeks aheadExact sum: 12.9 + 18.9 + 11 + 4.7 = 47.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Gujarat Themis Biosyn LtdGUJTHEM · turning · mixed, leaning weak · 83% evidence47.0out of 100
How the score adds up
Growth & earnings 9.9/35 · Revenue 15% · PAT −11.2% · OPM change −12.1 pp · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.1% (year to Mar 2026) · OPM 37.4% · 100% evidenceValuation 8.7/20 · P/E 95.2× · PEG — · 15% evidenceRelative strength 10.4/20 · RS sector −8.5% · RS bench 3.1% · 1Y −12.1% · 100% evidence · 8 of 12 weeks aheadExact sum: 9.9 + 18 + 8.7 + 10.4 = 47 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Wanbury LtdWANBURY · basing · mixed, leaning weak · 68% evidence44.7out of 100
- 12Fermenta Biotech LtdFERMENTA · fading · mixed, leaning weak · 68% evidence40.4out of 100
- 13Orchid Pharma LtdORCHPHARMA · quiet · mixed, leaning weak · 66% evidence39.7out of 100
- 14Themis Medicare LtdTHEMISMED · quiet · weak · 71% evidence31.5out of 100
How this score is built, and what the marks mean
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
How have Pharma API share prices moved?
Ind-Swift Laboratories Ltd has the strongest one-year price move in Pharma - API at +234.9%. It also leads on relative strength against the NIFTY, at +71.3%. 11 of 14 companies we track are ahead of the index on that measure. Every line covers 314 weekly closes through 13 November 2026.
Price and relative strength
Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
RS vs sector: The same measure taken against Pharma - API itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
Biggest one-year moves
- 1Ind-Swift Laboratories LtdINDSWFTLAB · ₹2,930 cr+234.9%1 year
- 2Kopran LtdKOPRAN · ₹1,290 cr+106.8%1 year
- 3Fermenta Biotech LtdFERMENTA · ₹1,340 cr+63.8%1 year
- 4Aarti Pharmalabs LtdAARTIPHARM · ₹9,190 cr+46.0%1 year
- 5Innova Captab LtdINNOVACAP · ₹6,010 cr+38.3%1 year
Strongest against NIFTY 500
- 1Ind-Swift Laboratories LtdINDSWFTLAB · ₹2,930 cr+71.3%vs NIFTY 500
- 2Kopran LtdKOPRAN · ₹1,290 cr+55.1%vs NIFTY 500
- 3Innova Captab LtdINNOVACAP · ₹6,010 cr+29.8%vs NIFTY 500
- 4Aarti Pharmalabs LtdAARTIPHARM · ₹9,190 cr+28.3%vs NIFTY 500
- 5Aarti Drugs LtdAARTIDRUGS · ₹4,620 cr+24.1%vs NIFTY 500
Strongest against the sector itself
- 1Ind-Swift Laboratories LtdINDSWFTLAB · ₹2,930 cr+59.5%vs sector
- 2Innova Captab LtdINNOVACAP · ₹6,010 cr+17.1%vs sector
- 3Aarti Drugs LtdAARTIDRUGS · ₹4,620 cr+10.1%vs sector
- 4Senores Pharmaceuticals LtdSENORES · ₹5,030 cr−4.1%vs sector
- 5Gujarat Themis Biosyn LtdGUJTHEM · ₹4,720 cr−8.5%vs sector
Why are Pharma API stocks moving?
The whole curve shows repeated runs and setbacks rather than a fresh escape from years of depressed prices. Price weakened through the earlier years, surged from the 2020 low, fell through 2022, and then made another large run into 2024. In the week of 5 October 2026, 92.9% of 14 Pharma - API companies were beating the Nifty 500, against 64.3% on 25 May 2026.
Pharma - API: share of companies beating the Nifty 500, and above their 200-day average, to 5 October 2026, last sector review
- Beating the Nifty 500 92.9%
- Above the 200-day average 71.4%
| Week | Beating the Nifty 500 | Above the 200-day average |
|---|---|---|
| 25 May 2026 | 64.3% | 64.3% |
| 1 Jun 2026 | 64.3% | 71.4% |
| 8 Jun 2026 | 78.6% | 71.4% |
| 15 Jun 2026 | 71.4% | 71.4% |
| 22 Jun 2026 | 78.6% | 78.6% |
| 29 Jun 2026 | 78.6% | 78.6% |
| 6 Jul 2026 | 78.6% | 85.7% |
| 13 Jul 2026 | 78.6% | 85.7% |
| 20 Jul 2026 | 71.4% | 85.7% |
| 27 Jul 2026 | 78.6% | 71.4% |
| 3 Aug 2026 | 64.3% | 71.4% |
| 10 Aug 2026 | 78.6% | 71.4% |
| 17 Aug 2026 | 92.9% | 85.7% |
| 24 Aug 2026 | 92.9% | 92.9% |
| 31 Aug 2026 | 92.9% | 92.9% |
| 7 Sep 2026 | 92.9% | 92.9% |
| 14 Sep 2026 | 92.9% | 92.9% |
| 21 Sep 2026 | 92.9% | 92.9% |
| 28 Sep 2026 | 92.9% | 92.9% |
| 5 Oct 2026 | 92.9% | 71.4% |
From our industry review of 10 October 2026.
What is changing for Pharma API companies?
New products, overseas expansion and better use of existing plants support recovery across several companies. But the ingredient makers disagree on how lasting the margin improvement is, and several have reduced forecasts or delayed projects.
| What is changing | Which companies | Lasting? |
|---|---|---|
| Higher-value products and a better mix | Aarti Pharmalabs, Ind-Swift and Jagsonpal describe shifts toward higher-value work or products. | looks lasting |
| New regions and countries | Senores, Orchid and Beta describe overseas launches or expansion. | looks lasting |
| New products | Senores has a commercialization program; Jagsonpal reports a launch; Beta and Orchid have further products planned. | looks lasting |
| Costs spread over more sales | Innova Captab reports better plant economics; Aarti Drugs and Ind-Swift describe gains from higher output and efficiency. | too early to call |
From our industry review of 10 October 2026.
Which other industries affect Pharma API stocks?
1 chain of cause and effect links Pharma - API to other industries right now. Drug profits favour complex contracted work over undifferentiated ingredients. For Pharma - API: Pricing normalisation and reduced forecasts offset opportunities at stronger individual companies.
Drug profits favour complex contracted work over undifferentiated ingredients hurts Pharma - API
What started it: The previous assessment of calls from July 27 to August 14, 2026 reported higher gross margins at 9 of 10 Pharma - API & CRAMS companies and 19% growth in Indian contract drug research and manufacturing. The October 10 verdicts provide further company evidence, but no updated industry growth percentage.
For Pharma - API: Pricing normalisation and reduced forecasts offset opportunities at stronger individual companies.
Also affected: Pharma - API & CRAMS (helps), Speciality Chemicals (helps), Pharma - Formulators (hurts)
✓ fact Evidence: high.
From our cross-industry review of 10 October 2026.
Which Pharma API companies have the most revenue, and which grow fastest?
Aarti Drugs Ltd has the highest Revenue among the 14 Pharma - API companies compared here, at ₹2,851 crore. Aarti Pharmalabs Ltd is next at ₹2,161 crore. Senores Pharmaceuticals Ltd has the highest Revenue growth at 38.9%, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Aarti Drugs Ltd is the largest at ₹2,851 crore, 31.9% ahead of Aarti Pharmalabs Ltd. Senores Pharmaceuticals Ltd's growth is 38.9% from a ₹718 crore base, with 12 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.
What this means: Aarti Drugs Ltd is the size to compare against; Senores Pharmaceuticals Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.
This conclusion weakens if: Aarti Drugs Ltd's growth falls below Senores Pharmaceuticals Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenue · company comparison
Revenue · largest
- 1Aarti Drugs LtdAARTIDRUGS₹2,850 cr
- 2Aarti Pharmalabs LtdAARTIPHARM₹2,160 cr
- 3Innova Captab LtdINNOVACAP₹1,870 cr
- 4Orchid Pharma LtdORCHPHARMA₹1,220 cr
- 5Kopran LtdKOPRAN₹794 cr
Revenue growth · fastest growers
- 1Senores Pharmaceuticals LtdSENORES39%
- 2Innova Captab LtdINNOVACAP37%
- 3Kopran LtdKOPRAN34%
- 4Ind-Swift Laboratories LtdINDSWFTLAB30%
- 5Orchid Pharma LtdORCHPHARMA20%
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Aarti Drugs Ltd AARTIDRUGS | ₹826 cr | 26% | Sep 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | ₹610 cr | 46% | Sep 2026 |
| Innova Captab Ltd INNOVACAP | ₹496 cr | 31% | Sep 2026 |
| Orchid Pharma Ltd ORCHPHARMA | ₹341 cr | 14% | Sep 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB | ₹240 cr | 51% | Sep 2026 |
| Kopran Ltd KOPRAN | ₹211 cr | 79% | Sep 2026 |
| Senores Pharmaceuticals Ltd SENORES | ₹192 cr | 19% | Sep 2026 |
| Anuh Pharma Ltd ANUHPHR | ₹185 cr | −0.5% | Sep 2026 |
| Wanbury Ltd WANBURY | ₹183 cr | 14% | Sep 2026 |
| Beta Drugs Ltd BETA | ₹137 cr | 33% | Sep 2026 |
| Fermenta Biotech Ltd FERMENTA | ₹133 cr | 1.9% | Sep 2026 |
| Themis Medicare Ltd THEMISMED | ₹87 cr | −11% | Jun 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM | ₹81 cr | 9.5% | Sep 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | ₹47.5 cr | 12% | Sep 2026 |
Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.
What to watch
Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.
Which Pharma API companies keep the most from each ₹100 of sales?
Gujarat Themis Biosyn Ltd has the highest OPM among the 14 Pharma - API companies compared here, at 37.4%. Senores Pharmaceuticals Ltd is next at 30.2%. Ind-Swift Laboratories Ltd has the highest Margin change at +14.3 percentage points, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Gujarat Themis Biosyn Ltd leads opm at 37.4%; Ind-Swift Laboratories Ltd leads margin change at +14.3 percentage points.
What this means: Gujarat Themis Biosyn Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
Operating margin · company comparison
OPM, by reported quarter
- Gujarat Themis Biosyn 37%
- Senores Pharmaceuticals 30%
- Aarti Pharmalabs 22%
- Beta Drugs 22%
- Jagsonpal Pharmaceuticals 21%
| Quarter | Gujarat Themis Biosyn | Senores Pharmaceuticals | Aarti Pharmalabs | Beta Drugs | Jagsonpal Pharmaceuticals |
|---|---|---|---|---|---|
| Dec 2021 | 53% | — | 14% | — | 10% |
| Mar 2022 | 45% | — | 16% | 24% | 1.5% |
| Jun 2022 | 51% | — | 19% | — | 12% |
| Sep 2022 | 51% | — | 17% | 24% | 21% |
| Dec 2022 | 43% | — | 18% | — | 14% |
| Mar 2023 | 52% | — | 16% | 23% | 9.8% |
| Jun 2023 | 47% | — | 19% | — | 14% |
| Sep 2023 | 42% | — | 20% | 23% | 14% |
| Dec 2023 | 46% | 19% | 21% | — | 7.0% |
| Mar 2024 | 50% | 22% | 23% | 18% | 6.0% |
| Jun 2024 | 48% | 27% | 17% | — | 17% |
| Sep 2024 | 44% | 23% | 20% | 22% | 22% |
| Dec 2024 | 48% | 25% | 24% | 21% | 21% |
| Mar 2025 | 43% | 17% | 26% | 18% | 15% |
| Jun 2025 | 39% | 25% | 24% | 20% | 19% |
| Sep 2025 | 49% | 31% | 18% | 21% | 22% |
| Dec 2025 | 49% | 29% | 24% | 19% | 22% |
| Mar 2026 | 44% | 27% | 19% | 19% | 17% |
| Jun 2026 | 48% | 30% | 25% | 22% | 21% |
| Sep 2026 | 37% | 30% | 22% | 22% | 21% |
Margin change, by reported quarter
- Gujarat Themis Biosyn −12.1 pp
- Senores Pharmaceuticals −1.0 pp
- Aarti Pharmalabs +4.0 pp
- Beta Drugs +1.0 pp
- Jagsonpal Pharmaceuticals −1.0 pp
| Quarter | Gujarat Themis Biosyn | Senores Pharmaceuticals | Aarti Pharmalabs | Beta Drugs | Jagsonpal Pharmaceuticals |
|---|---|---|---|---|---|
| Dec 2021 | +8.9 pp | — | — | — | −1.1 pp |
| Mar 2022 | +9.9 pp | — | — | +2.0 pp | −10.4 pp |
| Jun 2022 | −0.9 pp | — | — | — | −5.3 pp |
| Sep 2022 | −1.5 pp | — | — | +1.0 pp | +5.5 pp |
| Dec 2022 | −9.7 pp | — | +4.3 pp | — | +3.7 pp |
| Mar 2023 | +6.5 pp | — | −0.4 pp | −1.0 pp | +8.3 pp |
| Jun 2023 | −3.7 pp | — | +0.2 pp | — | +2.2 pp |
| Sep 2023 | −8.9 pp | — | +3.1 pp | −1.0 pp | −7.3 pp |
| Dec 2023 | +2.6 pp | — | +3.0 pp | — | −7.0 pp |
| Mar 2024 | −2.2 pp | — | +7.0 pp | −5.0 pp | −3.8 pp |
| Jun 2024 | +0.8 pp | — | −2.0 pp | — | +3.0 pp |
| Sep 2024 | +2.0 pp | — | 0.0 pp | −1.0 pp | +8.0 pp |
| Dec 2024 | +2.2 pp | +6.0 pp | +3.0 pp | — | +14.0 pp |
| Mar 2025 | −7.3 pp | −5.0 pp | +3.0 pp | 0.0 pp | +9.0 pp |
| Jun 2025 | −9.0 pp | −2.0 pp | +7.0 pp | — | +2.0 pp |
| Sep 2025 | +5.1 pp | +8.0 pp | −2.0 pp | −1.0 pp | 0.0 pp |
| Dec 2025 | +1.4 pp | +4.0 pp | 0.0 pp | −2.0 pp | +1.0 pp |
| Mar 2026 | +1.3 pp | +10.0 pp | −7.0 pp | +1.0 pp | +2.0 pp |
| Jun 2026 | +8.7 pp | +5.0 pp | +1.0 pp | +2.0 pp | +2.0 pp |
| Sep 2026 | −12.1 pp | −1.0 pp | +4.0 pp | +1.0 pp | −1.0 pp |
14 of 14 companies report OPM, 14 of 14 margin change.
OPM · highest
- 1Gujarat Themis Biosyn LtdGUJTHEM37%
- 2Senores Pharmaceuticals LtdSENORES30%
- 3Aarti Pharmalabs LtdAARTIPHARM22%
- 4Beta Drugs LtdBETA22%
- 5Jagsonpal Pharmaceuticals LtdJAGSNPHARM21%
Margin change · fastest expanders
- 1Ind-Swift Laboratories LtdINDSWFTLAB+14.3 pp
- 2Kopran LtdKOPRAN+11.8 pp
- 3Orchid Pharma LtdORCHPHARMA+6.0 pp
- 4Aarti Pharmalabs LtdAARTIPHARM+4.0 pp
- 5Aarti Drugs LtdAARTIDRUGS+3.0 pp
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Gujarat Themis Biosyn Ltd GUJTHEM | 37% | −12.1 pp | Sep 2026 |
| Senores Pharmaceuticals Ltd SENORES | 30% | −1.0 pp | Sep 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | 22% | +4.0 pp | Sep 2026 |
| Beta Drugs Ltd BETA | 22% | +1.0 pp | Sep 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM | 21% | −1.0 pp | Sep 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB | 19% | +14.3 pp | Sep 2026 |
| Aarti Drugs Ltd AARTIDRUGS | 16% | +3.0 pp | Sep 2026 |
| Fermenta Biotech Ltd FERMENTA | 15% | −5.3 pp | Sep 2026 |
| Innova Captab Ltd INNOVACAP | 14% | 0.0 pp | Sep 2026 |
| Wanbury Ltd WANBURY | 12% | −3.7 pp | Sep 2026 |
| Anuh Pharma Ltd ANUHPHR | 9.0% | +3.0 pp | Sep 2026 |
| Kopran Ltd KOPRAN | 7.3% | +11.8 pp | Sep 2026 |
| Orchid Pharma Ltd ORCHPHARMA | 7.0% | +6.0 pp | Sep 2026 |
| Themis Medicare Ltd THEMISMED | −60% | −50.0 pp | Jun 2026 |
What to watch
Watch whether the next two comparable periods confirm the current margin change rather than reversing it.
Which Pharma API companies earn the most profit?
Aarti Pharmalabs Ltd has the highest Net profit among the 14 Pharma - API companies compared here, at ₹256 crore. Aarti Drugs Ltd is next at ₹229 crore. Senores Pharmaceuticals Ltd has the highest Profit growth at 62.4%, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Aarti Pharmalabs Ltd earns the most, ₹256 crore of profit over the last 12 months, 11.8% above Aarti Drugs Ltd. Senores Pharmaceuticals Ltd shows 62.4% growth from a profit base of ₹138 crore. A fast rate from a small base matters less than a large profit that keeps coming.
What this means: Aarti Pharmalabs Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profit · company comparison
Net profit · largest
- 1Aarti Pharmalabs LtdAARTIPHARM₹256 cr
- 2Aarti Drugs LtdAARTIDRUGS₹229 cr
- 3Innova Captab LtdINNOVACAP₹166 cr
- 4Senores Pharmaceuticals LtdSENORES₹138 cr
- 5Ind-Swift Laboratories LtdINDSWFTLAB₹84 cr
Profit growth · fastest growers
- 1Senores Pharmaceuticals LtdSENORES62%
- 2Innova Captab LtdINNOVACAP33%
- 3Beta Drugs LtdBETA26%
- 4Anuh Pharma LtdANUHPHR24%
- 5Aarti Drugs LtdAARTIDRUGS15%
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Aarti Drugs Ltd AARTIDRUGS | ₹83 cr | 84% | Sep 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | ₹71 cr | 154% | Sep 2026 |
| Innova Captab Ltd INNOVACAP | ₹42 cr | 40% | Sep 2026 |
| Senores Pharmaceuticals Ltd SENORES | ₹37 cr | 23% | Sep 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB | ₹34 cr | 325% | Sep 2026 |
| Orchid Pharma Ltd ORCHPHARMA | ₹29 cr | 18% | Sep 2026 |
| Themis Medicare Ltd THEMISMED | ₹25 cr | 900% | Jun 2026 |
| Beta Drugs Ltd BETA | ₹19 cr | 58% | Sep 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM | ₹13 cr | 0.0% | Sep 2026 |
| Anuh Pharma Ltd ANUHPHR | ₹11 cr | 38% | Sep 2026 |
| Fermenta Biotech Ltd FERMENTA | ₹9.4 cr | −48% | Sep 2026 |
| Wanbury Ltd WANBURY | ₹8.5 cr | −44% | Sep 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | ₹8.5 cr | −41% | Sep 2026 |
| Kopran Ltd KOPRAN | ₹4.4 cr | −10% | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.
Which Pharma API companies earn the best return on capital?
Wanbury Ltd has the highest ROCE among the 14 Pharma - API companies compared here, at 36.6%. Jagsonpal Pharmaceuticals Ltd is next at 22.7%. Themis Medicare Ltd has the highest ROCE change at +14.6 percentage points, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Wanbury Ltd leads ROCE at 36.6%, 13.9 percentage points above Jagsonpal Pharmaceuticals Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.
What this means: Wanbury Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
Return on capital · company comparison
Withheld from this chart: Senores Pharmaceuticals Ltd (SENORES): its two data sources disagree by up to 13% on reported income across 11 comparable periods, so its derived ratios are withheld; Ind-Swift Laboratories Ltd (INDSWFTLAB): its two data sources disagree by up to 277% on reported income across 15 comparable periods, so its derived ratios are withheld; Beta Drugs Ltd (BETA): its two data sources disagree by up to 50% on reported income across 13 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn, the gap is a decision, not missing data.
ROCE · highest
- 1Wanbury LtdWANBURY37%
- 2Jagsonpal Pharmaceuticals LtdJAGSNPHARM23%
- 3Fermenta Biotech LtdFERMENTA21%
- 4Gujarat Themis Biosyn LtdGUJTHEM18%
ROCE change · fastest improvers
- 1Themis Medicare LtdTHEMISMED+14.6 pp
- 2Kopran LtdKOPRAN+5.0 pp
- 3Anuh Pharma LtdANUHPHR+4.4 pp
- 4Jagsonpal Pharmaceuticals LtdJAGSNPHARM+2.7 pp
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Wanbury Ltd WANBURY | 22% | −8.1 pp | Sep 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM | 20% | +2.7 pp | Sep 2026 |
| Gujarat Themis Biosyn Ltd GUJTHEM | 20% | −5.0 pp | Sep 2026 |
| Anuh Pharma Ltd ANUHPHR | 19% | +4.4 pp | Sep 2026 |
| Innova Captab Ltd INNOVACAP | 17% | +1.6 pp | Sep 2026 |
| Aarti Drugs Ltd AARTIDRUGS | 16% | +1.8 pp | Sep 2026 |
| Themis Medicare Ltd THEMISMED | 16% | +14.6 pp | Jun 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | 14% | −4.4 pp | Sep 2026 |
| Fermenta Biotech Ltd FERMENTA | 14% | −15.7 pp | Sep 2026 |
| Kopran Ltd KOPRAN | 13% | +5.0 pp | Sep 2026 |
| Orchid Pharma Ltd ORCHPHARMA | 1.6% | −3.5 pp | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current roce change rather than reversing it.
How are Pharma API stocks valued against growth and quality?
No company in this Pharma - API comparison reports a valuation figure this section can compare, so the PEG rank is empty. On P/E, Wanbury Ltd is lowest at 12.4× at the latest share price, across 14 of 14 companies with a usable reading.
What the numbers say: There is not enough comparable evidence to name a reliable peg leader.
What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
Valuation · company comparison
PEG, by reported quarter
- Aarti Pharmalabs 5.5
- Innova Captab 2.6
- Orchid Pharma 1.8
- Gujarat Themis Biosyn 10.1
- Aarti Drugs 1.4
| Quarter | Aarti Pharmalabs | Innova Captab | Orchid Pharma | Gujarat Themis Biosyn | Aarti Drugs |
|---|---|---|---|---|---|
| Dec 2021 | — | — | — | 2.7 | — |
| Mar 2022 | — | — | — | — | — |
| Jun 2022 | — | — | — | — | — |
| Sep 2022 | — | — | — | 0.7 | — |
| Dec 2022 | — | — | — | 0.6 | — |
| Mar 2023 | — | — | — | — | — |
| Jun 2023 | — | — | — | — | — |
| Sep 2023 | — | — | — | 1.3 | — |
| Dec 2023 | — | — | — | — | — |
| Mar 2024 | — | — | — | — | — |
| Jun 2024 | — | — | — | — | — |
| Sep 2024 | 1.5 | — | — | — | — |
| Dec 2024 | 1.3 | — | — | — | — |
| Mar 2025 | 1.0 | — | 1.8 | — | — |
| Jun 2025 | 1.1 | 1.1 | — | — | — |
| Sep 2025 | 1.5 | 2.2 | — | — | 3.2 |
| Dec 2025 | 5.5 | — | — | — | — |
| Mar 2026 | — | — | — | — | — |
| Jun 2026 | — | 4.1 | — | — | — |
| Sep 2026 | — | 2.6 | — | 10.1 | 1.4 |
P/E, by reported quarter
- Aarti Pharmalabs 38.7×
- Innova Captab 47.6×
- Senores Pharmaceuticals 49.4×
- Orchid Pharma 289.9×
- Gujarat Themis Biosyn 94.0×
| Quarter | Aarti Pharmalabs | Innova Captab | Senores Pharmaceuticals | Orchid Pharma | Gujarat Themis Biosyn |
|---|---|---|---|---|---|
| Dec 2021 | — | — | — | — | 17.3× |
| Mar 2022 | — | — | — | — | 15.8× |
| Jun 2022 | — | — | — | — | 13.7× |
| Sep 2022 | — | — | — | — | 19.0× |
| Dec 2022 | — | — | — | −76.6× | 21.1× |
| Mar 2023 | 20.4× | — | — | — | 17.8× |
| Jun 2023 | 17.4× | — | — | 182.7× | 19.9× |
| Sep 2023 | 21.6× | — | — | 70.4× | 25.7× |
| Dec 2023 | 24.1× | 46.7× | — | 56.9× | 36.0× |
| Mar 2024 | 20.3× | 38.8× | — | 62.1× | 52.4× |
| Jun 2024 | 25.5× | 30.8× | — | 62.7× | 57.6× |
| Sep 2024 | 24.8× | 41.6× | — | 64.8× | 73.5× |
| Dec 2024 | 26.9× | 52.3× | 55.1× | 77.2× | 62.9× |
| Mar 2025 | 27.2× | 39.5× | 83.5× | 35.7× | 58.3× |
| Jun 2025 | 28.6× | 38.4× | 39.7× | 36.0× | 78.1× |
| Sep 2025 | 28.0× | 37.7× | 44.0× | 56.6× | 97.7× |
| Dec 2025 | 28.1× | 31.6× | 43.5× | 106.0× | 100.0× |
| Mar 2026 | 25.6× | 29.9× | 35.7× | 249.8× | 57.4× |
| Jun 2026 | 35.4× | 38.4× | 50.7× | 282.6× | 91.8× |
| Sep 2026 | 38.7× | 47.6× | 49.4× | 289.9× | 94.0× |
0 of 14 companies report PEG, 14 of 14 P/E.
PEG · lowest PEG
Not enough comparable data.
P/E · lowest P/E
- 1Wanbury LtdWANBURY12.4×
- 2Anuh Pharma LtdANUHPHR16.7×
- 3Aarti Drugs LtdAARTIDRUGS20.2×
- 4Themis Medicare LtdTHEMISMED22.2×
- 5Fermenta Biotech LtdFERMENTA26.1×
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Gujarat Themis Biosyn Ltd GUJTHEM | 10.1 | 94.0× | Sep 2026 |
| Aarti Pharmalabs Ltd AARTIPHARM | 5.5 | 38.7× | Sep 2026 |
| Jagsonpal Pharmaceuticals Ltd JAGSNPHARM | 3.4 | 34.3× | Sep 2026 |
| Innova Captab Ltd INNOVACAP | 2.6 | 47.6× | Sep 2026 |
| Orchid Pharma Ltd ORCHPHARMA | 1.8 | 289.9× | Sep 2026 |
| Aarti Drugs Ltd AARTIDRUGS | 1.4 | 20.2× | Sep 2026 |
| Kopran Ltd KOPRAN | 1.0 | 54.3× | Sep 2026 |
| Wanbury Ltd WANBURY | 0.6 | 18.2× | Sep 2026 |
| Anuh Pharma Ltd ANUHPHR | 0.3 | 20.4× | Sep 2026 |
| Senores Pharmaceuticals Ltd SENORES | — | 49.4× | Sep 2026 |
| Ind-Swift Laboratories Ltd INDSWFTLAB | — | 53.4× | Sep 2026 |
| Beta Drugs Ltd BETA | — | 51.2× | Sep 2026 |
| Fermenta Biotech Ltd FERMENTA | — | 25.7× | Sep 2026 |
| Themis Medicare Ltd THEMISMED | — | 25.2× | Jun 2026 |
What to watch
Watch whether the next two comparable periods confirm the current p/e rather than reversing it.
Which stock lists do Pharma API companies appear on?
Pharma - API companies show up on 5 of our India lists. The most are on the pharma stocks list (14 companies).
What can make this comparison misleading?
This Pharma - API comparison names 6 specific ways its own evidence can mislead, all listed below. All 14 companies here report on comparable dates, so no rank carries a stale marker. 3 have second-source figures left out because the two sources disagree. 1 of the 5 ranked sections has fewer than three usable current readings.
Keep these limits visible
- A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
- A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
- The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 3 companies are missing from the second-source figures on purpose: the two sources disagree, so nothing from the second is drawn. Those rows have less evidence; that does not make the business weaker.
- Thin comparisons: Valuation have fewer than three usable current readings.
How was this comparison built?
This comparison is built from the reported filings of 14 Pharma - API companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 13 November 2026.
3 of 14 companies have a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Senores Pharmaceuticals Ltd (SENORES): its two data sources disagree by up to 13% on reported income across 11 comparable periods, so its derived ratios are withheld; Ind-Swift Laboratories Ltd (INDSWFTLAB): its two data sources disagree by up to 277% on reported income across 15 comparable periods, so its derived ratios are withheld; Beta Drugs Ltd (BETA): its two data sources disagree by up to 50% on reported income across 13 comparable periods, so its derived ratios are withheld.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree, the figures are simply used. Where there is too little shared history to compare, the figures are still drawn, they are the only evidence there is, and marked unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
What else do people ask about Pharma API stocks?
These 22 answers restate the Pharma - API comparison above in question form. Every one is computed from the same 14 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 13 November 2026. Nothing here is estimated, and none of it is a recommendation.
Is the Pharma API sector outperforming NIFTY 500?
Pharma - API has done better than the NIFTY 500 by 20.4% over 52 weeks and by 2.6% over 13 weeks.
7 of 14 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 3 of the 8 with a long enough price history are ahead of the industry itself.
Which Pharma API company is largest by revenue?
Aarti Drugs Ltd leads with revenue of ₹2,851 crore, based on 14 of 14 comparable companies through Sep 2026.
Which Pharma API company is growing fastest?
Senores Pharmaceuticals Ltd has the fastest current revenue growth at 38.9%, across 14 of 14 comparable companies.
Which Pharma API company has the strongest 4-Factor Sector Score?
Innova Captab Ltd ranks first at 66.5 out of 100, with 90% of the evidence available. The score ranks published data; it is not a recommendation.
How much history does this Pharma API comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.
Is there a Nifty Pharma API index?
The exchange runs Nifty indices for several broad sectors, such as Nifty Bank, Nifty IT and Nifty Pharma, but not for every smaller group on this site.
Whether or not an official Nifty index covers Pharma - API, this page builds its own equal-weight basket of 14 listed Pharma - API companies: one company, one vote, whatever its size, so no single large company dominates. Figures are as of Sep 2026.
Which are the best Pharma API stocks in India?
Ranked by this page's four-factor score, Innova Captab Ltd comes first among 14 listed Pharma - API companies, followed by Aarti Drugs Ltd. That is a ranking of published data (earnings, quality, valuation and share-price behaviour as of Sep 2026), not a recommendation.
How many Pharma API stocks are listed in India?
This comparison covers 14 listed Pharma - API companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Sep 2026.
Which Pharma API company is the biggest?
Aarti Drugs Ltd is the largest, with revenue of ₹2,851 crore over the last 12 months, ahead of Aarti Pharmalabs Ltd at ₹2,161 crore. That covers 14 of 14 companies with comparable reporting through Sep 2026.
Which Pharma API company has the best profit margins?
Gujarat Themis Biosyn Ltd has the highest operating margin at 37.4%, from 14 of 14 comparable companies. Ind-Swift Laboratories Ltd shows the biggest recent improvement, at +14.3 percentage points. A high margin matters most when it is steady or rising, not when it is at a peak.
Which Pharma API company makes the most profit?
Aarti Pharmalabs Ltd earns the most, at ₹256 crore of net profit over the last 12 months, from 14 of 14 comparable companies. Senores Pharmaceuticals Ltd has the fastest profit growth at 62.4%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Pharma API company earns the highest return on capital?
Wanbury Ltd leads on return on capital employed at 36.6%, across 14 of 14 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.
Is the Pharma API sector beating the market?
Pharma - API has done better than the NIFTY 500 by 20.4% over the last 52 weeks and by 2.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 7 of the 14 companies we track are beating the market on their own.
Sector strength does not transfer evenly to every stock in it.
Which Pharma API stock has the strongest price momentum?
Ind-Swift Laboratories Ltd has the strongest relative strength against the NIFTY 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.
Which Pharma API company has the highest 4-Factor score?
Innova Captab Ltd scores 66.5 out of 100, with 90% of the evidence available, from 25.5 points on growth and earnings, 12.4 on capital efficiency, 11.6 on valuation and 17 on relative strength. It ranks published data only; management quality, upcoming events and risks are not part of the score.
How many Pharma API companies does this comparison cover, and over what period?
This comparison covers 14 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.
What is the total market cap of the Pharma API sector?
The 14 Pharma - API companies on this page carry ₹46,524 crore of combined market value. Aarti Pharmalabs Ltd is the largest at ₹9,189 crore, about 20% of the sector's total on its own. Market value moves with price, so this reading is dated 13 November 2026.
What is the Pharma API sector's P/E ratio?
The median price-to-earnings ratio across the 14 Pharma - API companies on this page is 34.8×, measured on the 14 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past.
Figures are as of 13 November 2026.
How is the Pharma API sector performing?
7 of the 14 Pharma - API companies we track are doing better than the NIFTY 500 on relative strength (how a share price has done against the index over recent months).
The sector itself is 20.4% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 13 November 2026.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.
Is this advice?
No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
Every India sector against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 13 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.